- Ocugen (OCGN, Financial) to announce Q2 2025 financial results on August 1, 2025, before market open.
- Earnings call scheduled for 8:30 a.m. ET on the same day, accessible via phone and webcast.
- Replay of the call will be available for 45 days on Ocugen's investor site.
Ocugen, Inc. (OCGN), a biotechnology company specializing in gene therapies for blindness diseases, has announced it will release its second quarter 2025 financial results on Friday, August 1, 2025, before the market opens.
The company will host a conference call and live webcast at 8:30 a.m. ET on the same day to discuss the earnings and provide a business update. Investors in the United States can join the call by dialing (800) 715-9871, while international participants can use (646) 307-1963 with the conference ID 9627149.
The webcast will be available on Ocugen's investor relations website, and a replay will be accessible for approximately 45 days post-event.
Ocugen continues to be a leader in the biotechnology space with its innovative gene therapies targeting complex blindness diseases, including retinitis pigmentosa and Stargardt disease. The company's pioneering approach focuses on addressing the entire disease spectrum through modifier gene therapies.
